Medicine & Research - 2004
| 19.03.2004 | Fresenius receives Orphan Drug Designation for antibody removab® to treat patients with ovarian cancer |
 Text as PDF-file |
Fresenius SE
- WHO WE ARE
- INVESTOR RELATIONS
- PRESS
- HEALTHCARE
- CAREER
Share Price
Next Event
To view PDF-files you need Adobe Reader. You can download this software free of charge.